- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04751162
A Study To Monitor Lung Cancer Patients Activity And Assess Performance Status Through A Wearable Device. (Lupa-01)
An Observational Study To Monitor Lung Cancer Patients Activity And Assess Performance Status Through A Wearable Device.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Global Medical Information:
- Email: global.medical_information@roche.com
Study Contact Backup
- Name: Reference Study ID ML42283 https://forpatients.roche.com/
- Phone Number: 888-662-6728 (U.S.)
- Email: global-roche-genentech-trials@gene.com
Study Locations
-
-
-
Barcelona, Spain, 08041
- Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia
-
Girona, Spain, 17007
- Hospital Universitari de Girona Dr Josep Trueta; Departamento de Oncologia Medica
-
Granada, Spain, 18016
- Hospital Universitario Clínico San Cecilio; Servicio de oncologia
-
Madrid, Spain, 28046
- Hospital La Paz
-
Madrid, Spain, 28041
- Hospital 12 de Octubre; Servicio de Digestivo
-
Murcia, Spain, 30120
- Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia
-
Sevilla, Spain, 41013
- Hospital Universitario Virgen del Rocio; Servicio de Oncologia
-
Tarragona, Spain, 43003
- Hospital Sant Pau i Santa Tecla; Servicio de Oncologia
-
Valencia, Spain, 46026
- Hospital Universitario la Fe; Servicio de Oncologia
-
-
Madrid
-
Alcorcon, Madrid, Spain, 28922
- Fundacion Hospital de Alcorcon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria
Participants must meet the following criteria for study entry:
- 18 or more years of age.
- Able to understand and provide the study informed consent.
- Able to demonstrate basic digital literacy (e.g. knows how to communicate through instant messaging apps or similar).
- ECOG PS of 0, 1 or 2 assessed by physician.
- Life expectancy ≥ 12 weeks
- Histopathologically or cytologically confirmed Non-small cell lung cancer (NSCLC) according to the International Association for the Study of Lung Cancer (IASLC) histopathological classification. Mixed or combined subtypes with component of small cell lung cancer according to the IASLC are not allowed.
- Metastatic NSCLC participants.
- Able to receive 1st line specific antitumor therapy defined by local practice and decision of attended oncologist.
Exclusion Criteria
Participants who meet any of the following criteria will be excluded from study entry:
- Any medical or social condition deemed by the investigator to be likely to interfere with a participant's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.
- Participants with advanced LC and a known sensitizing driver mutation: activating EGFR mutation, ALK gene rearrangement, ROS1+ gen rearrangement, BRAF mutation.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
Uncontrolled tumor-related pain. Participants requiring pain medication must be on a stable regimen at study entry. Symptomatic lesions amenable to palliative radiotherapy (e.g., bone metastases or metastasis causing nerve impingement) should be treated prior to enrollment. Asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epidural metastasis that is not presently associated with spinal cord compression) should be considered for locoregional therapy if appropriate prior to enrollment.
- Pregnant or breastfeeding woman.
- Leptomeningeal disease.
Participants with any of the following central nervous system (CNS) metastases:
- Symptomatic CNS metastases with need of increasing doses of corticosteroids.
- Carcinomatous meningitis.
- Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for ≥ 2 weeks prior to study entry.
- Oncological history:
- Have a previous or concurrent cancer that is distinct in primary (non-pulmonary) site or histology, except carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta and Tis [carcinoma in situ]) or any previous cancer curatively treated with last specific treatment more than 3 years ago without evidence of recurrence.
- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated with curative intent, or ductal carcinoma in situ treated surgically with curative intent).
Severe cardiovascular and pulmonary disease (e.g. myocardial infarction, unstable angina pectoris, coronary angioplasty or stenting, deep vein thrombosis, stroke, pulmonary fibrosis, active uncontrolled bleeding, or a known bleeding diathesis) less than 6 months before inclusion. New York Heart Association Class III or IV congestive heart failure, ventricular arrhythmias, or uncontrolled blood pressure.
- Any psychiatric diagnosis.
- Observed cognitive impairment or disease with cognitive impairment such as Alzheimer's Disease or Parkinson's Disease
- Severe infections within 4 weeks prior to randomization including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
- Major surgical procedure within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis.
- Inability to understand the local language.
- Allergic to dedicated wearable material.
- Currently enrolled in a Clinical Trial.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Phase I
Participants will be asked to wear an actigraphy device (wearable) and to install a mobile application on their smartphones for tracking PA, SQ and symptoms for 3 weeks The ECOG-PS will be assessed by clinician at both, baseline and subsequent visit after the 3 weeks.
|
Participants will be asked to wear an actigraphy device (wearable) and to install a mobile application on their smartphones (cf.
Broderick et al., 2019) for tracking PA, SQ and symptoms for 3 weeks
|
Phase II
Participants will be equipped with both devices (wearable and mobile application) for further monitoring during the following 9 weeks. Study participants will undergo scheduled visits according to local standard practice. The study will progress to Phase II just in case any of the following conditions are met at the end of Phase I:
|
Participants will be asked to wear an actigraphy device (wearable) and to install a mobile application on their smartphones (cf.
Broderick et al., 2019) for tracking PA, SQ and symptoms for 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ECOG-PS assessment of LC participants measured by clinical investigators
Time Frame: From baseline up to 9 months
|
ECOG-PS: Eastern Cooperative Oncology Group Performance Status (Oken et al., 1982)
|
From baseline up to 9 months
|
ECOG-PS assessment of LC participants measured by data collected through wearable and a mobile application
Time Frame: From baseline up to 9 months
|
ECOG-PS: Eastern Cooperative Oncology Group Performance Status (Oken et al., 1982)
|
From baseline up to 9 months
|
Usability of the mobile application perceived by clinical investigators
Time Frame: From baseline up to 9 months
|
System Usability: SUS questionnaire (Brooke, 1986) and usability questionnaire adapted from (Kim et al., 2017).
This is a 10-item scale based on a 5-point Likert response measuring strength and agreement of usability.
Total scores range from 0 to 100 with score = 68 considered acceptable usability.
|
From baseline up to 9 months
|
Usability of the mobile application perceived by LC participants
Time Frame: From baseline up to 9 months
|
System Usability: SUS questionnaire (Brooke, 1986) and usability questionnaire adapted from (Kim et al., 2017).
This is a 10-item scale based on a 5-point Likert response measuring strength and agreement of usability.
Total scores range from 0 to 100 with score = 68 considered acceptable usability.
|
From baseline up to 9 months
|
Usability of the wearable device perceived by LC participants
Time Frame: From baseline up to 9 months
|
System Usability: SUS questionnaire (Brooke, 1986) and usability questionnaire adapted from (Kim et al., 2017).
This is a 10-item scale based on a 5-point Likert response measuring strength and agreement of usability.
Total scores range from 0 to 100 with score = 68 considered acceptable usability.
|
From baseline up to 9 months
|
Usability of the wearable device perceived by clinical investigators
Time Frame: From baseline up to 9 months
|
System Usability: SUS questionnaire (Brooke, 1986) and usability questionnaire adapted from (Kim et al., 2017).
This is a 10-item scale based on a 5-point Likert response measuring strength and agreement of usability.
Total scores range from 0 to 100 with score = 68 considered acceptable usability.
|
From baseline up to 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity to changes in ECOG-PS over time measured by clinical investigators
Time Frame: From baseline up to 9 months
|
ECOG-PS: Eastern Cooperative Oncology Group Performance Status (Oken et al., 1982)
|
From baseline up to 9 months
|
Sensitivity to changes in ECOG-PS over time measured by wearable and mobile application
Time Frame: From baseline up to 9 months
|
ECOG-PS: Eastern Cooperative Oncology Group Performance Status (Oken et al., 1982)
|
From baseline up to 9 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ML42283
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Small Cell Lung Cancer (NSCLC)
-
H. Lee Moffitt Cancer Center and Research InstituteNestle Health ScienceWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢAUnited States
-
ElephasBeaufort CRORecruitingNSCLC | Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
Jun Zhang, MD, PhDGenentech, Inc.; ExelixisNot yet recruitingLung Cancer | NSCLC Stage IV | Advanced NSCLC | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingNSCLC | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Non-small Cell CarcinomaUnited States
-
University of Alabama at BirminghamSanofiCompletedNon-small Cell Lung Cancer (NSCLC) | Metastatic NSCLC | Stage IV NSCLCUnited States
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
Radiotherapy Oncology Centre "Santa Maria" HospitalPaola Anselmo,MD; Michelina Casale,PhD; Fabio Trippa,MDRecruitingNSCLC | Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Oligometastatic Disease | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Non-Small Cell Adenocarcinoma and other conditionsItaly
-
Heather WakeleeNovartis; Genentech, Inc.TerminatedNon-small Cell Lung Cancer (NSCLC), Recurrent | Non-small Cell Lung Cancer (NSCLC), Stage IVUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
Clinical Trials on Actigraphy device (wearable) and mobile application
-
Hanyang UniversityNational Institute of Health, KoreaCompletedTime Restricted Feeding | Non-Alcoholic Fatty Liver Disease | Mobile TechnologyKorea, Republic of
-
St. John's Research InstituteBill and Melinda Gates FoundationCompletedFever | Preterm Infant | Hypothermia, Newborn | Kangaroo Mother Care | Low Birth Weight InfantIndia
-
Boehringer IngelheimCompletedPulmonary FibrosisUnited States, Germany, Netherlands, Belgium
-
Avation Medical, Inc.Enrolling by invitationUrinary Incontinence | Urinary Urge IncontinenceUnited States
-
University of California, San FranciscoMount Zion Health FundNot yet recruitingHead and Neck Cancer | TrismusUnited States
-
University of California, San FranciscoCompleted
-
Wayne State UniversityTerminatedPregnancyUnited States
-
Huawei Device Co., LtdRecruiting
-
EyeQue Corp.CompletedRefractive Errors | AstigmatismUnited States
-
University of California, San DiegoCarol Vassiliadis FamilyCompletedObesity | Health BehaviorUnited States